06609 HEARTCARE-B
- 19.220
- 0.0000.00%
HEARTCARE-B News
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
心瑋醫療-B：年度報告 2023
Interpretation of Xinwei Medical-B (6609.HK) Annual Report: Innovation and Globalization, Therapeutic Products Save Development Potential
The concept of “new quality productivity” was emphasized many times during the two sessions. In particular, the medical device industry, the high-end medical device sector, which is driven by scientific and technological innovation as the core driving force, is undoubtedly also moving towards a rapid development path as an important indicator for measuring the country's level of high-tech development.
Xinwei Medical-B (06609.HK): Expected volume of therapeutic products in 2023 is slightly lower than expected
The 2023 results were slightly lower than our expectations for the company to announce 2023 results: revenue of $232 million, +27% year over year; net loss to mother of $94 million ($200 million in 2022). Due to 2H23
Xinwei Medical-B (06609.HK) announced annual results: business focus on driving product structure transformation, gross margin rose to 70.5%, losses narrowed, and major neurointerventional treatment devices are about to be launched
Gelonghui March 28 | Xinwei Medical-B (06609.HK) announced its annual results. For the year ended December 31, 2023, the company's revenue increased to RMB 232.3 million, an increase of 26.9% year on year, and loss before tax narrowed to RMB 102.9 million, a year-on-year decrease of 48.9%. With the expansion of business scale and the effects of cost control and efficiency measures, the company's gross margin increased 2.6 percentage points to 70.5%, and the share of sales and distribution expenses and administrative expenses decreased to 66.2% (2022:91.8%). In 2023, in order to adapt to a rapidly changing city
Xinwei Medical-B (06609) announced 2023 annual results with revenue of 232 million yuan, an increase of 26.9% year-on-year
Xinwei Medical-B (06609) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 232 million yuan (RMB, same below) during the period, an increase of 26.9%; the parent company's owners should have accounted for a loss of 94.012 million yuan, a year-on-year decrease of 53.08%; and a basic loss of 2.47 yuan per share.
HEARTCARE-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Xinwei Medical-B (06609.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui, March 18, 丨 Xinwei Medical-B (06609.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, consider recommending payment of a final dividend (if any), and handle any other business.
HEARTCARE-B: DATE OF BOARD MEETING
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Home to Linjiang: Brain-computer interface is a trend where Hong Kong stocks are not approved
As an emerging industry, brain-computer interface technology is mainly divided into hardware layer and software layer.
Hong Kong Stock Concept Tracking | Brain-computer interface ushered in a “milestone moment” Musk announced: the first time humans have implanted a brain-computer interface chip (with concept stock)
Musk announced on social networking platform X that the first human being received an implant from the brain-computer interface company Neuralink is recovering well.
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
Xinwei Medical-B (06609.HK) was increased by 237,200 H shares by Wisary Limited, worth approximately HK$5.0664 million
On January 29, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 29, Wisary Limited increased its holdings of $Xinwei Medical-B (06609.HK) $237,200 H shares at an average price of HK$21.36 per share on January 25, worth about HK$5.0664 million. After the increase in holdings, Wisary Limited's latest shareholding was 1.608 million shares, and the good position ratio increased from 4.32% to 5.07%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, majority shareholders (holding 5% or more of shares)
Xinwei Medical-B (06609.HK) obtained Ding Kui to increase its H share holdings by 1.363,600, worth approximately HK$28.2947 million
On January 26, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 26, Ding Kui increased her H shares of $Xinwei Medical-B (06609.HK) $1.3636 million at an average price of HK$20.75 per share on January 24, worth about HK$28.2947 million. After the increase in holdings, Ding Kui's latest shareholding was 782,900 shares, with a good position ratio of 2.48%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors of listed companies
Xinwei Medical-B (06609.HK) received 237,200 additional H shares by Ding Kui, worth about HK$5,066,400
On January 26, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 26, Ding Kui increased her H shares of $Xinwei Medical-B (06609.HK) by $237,200 at an average price of HK$21.36 per share on January 25, worth about HK$5.0664 million. After the increase in holdings, Ding Kui's latest shareholding was 2.383,700 shares, and the good position ratio increased from 6.80% to 7.55%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. public
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Financial News Agency Venture Capital Connect: In November, domestic healthcare financing of 5.931 billion yuan increased 49% month-on-month, and innovative drugs led the popularity
① In November 2023, there were 109 financing incidents in the domestic healthcare sector (excluding IPOs, targeted increases, etc.), a year-on-year decrease of 31% and an increase of 76% over the previous year; ② The total amount of financing disclosed in the healthcare sector during the same period was about 5.931 billion yuan, a decrease of 6% over the previous year and an increase of 49% over the previous year.
Analysis
Price Target
No Data
